Julie N. Graff

5.1k citations

104 papers · 3.2k indexed · 2 hit papers · h-index 25

Pulmonary and Respiratory Medicine top 1%
- Prostate Cancer Treatment and Research 84
- Prostate Cancer Diagnosis and Treatment 10
Cancer Research top 2%
- Cancer, Lipids, and Metabolism 19
Oncology top 2%
- Cancer Immunotherapy and Biomarkers 21
- PARP inhibition in cancer therapy 9
- Cancer Treatment and Pharmacology 7
Radiology, Nuclear Medicine and Imaging top 2%
- Radiopharmaceutical Chemistry and Applications 39
Immunology top 5%
- Immunotherapy and Immune Responses 10

Co-authors: Tomasz M. Beer Fred Saad Eric J. Small Angela Lopez‐Gitlitz Matthew R. Smith Boris Hadaschik Stéphane Oudard Paul N. Mainwaring
Cited by: Pulmonary and Respiratory Medicine Cancer Research Oncology
Journals: Nature (1 paper)New England Journal of Medicine (1 paper)Journal of Biological Chemistry (1 paper)
Partner nations: United States Canada United Kingdom

In The Last Decade

Julie N. Graff

99 papers receiving 3.2k citations

Hit Papers

align trajectories log scale

Peers

Countries citing papers authored by Julie N. Graff

Since Specialization

Citations

This map shows the geographic impact of Julie N. Graff's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Julie N. Graff with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Julie N. Graff more than expected).

Fields of papers citing papers by Julie N. Graff

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Julie N. Graff. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Julie N. Graff. The network helps show where Julie N. Graff may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Julie N. Graff, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Julie N. Graff Line = papers co-authored together Julie N. Graff links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Suffering in Silence: Loneliness Among Men with Prostate Cancer and the Potential for Exercise as Connection European Urology Oncology ·Kerri M. Winters‐Stone,Sydnee Stoyles,Nathan F. Dieckmann,Mary E. Crisafio,Alexandra Sokolova,Julie N. Graff,Arthur Hung,Karen S. Lyons	2025	0
2	Absence of the dolichol synthesis gene DHRSX leads to N-glycosylation defects in Lec5 and Lec9 Chinese hamster ovary cells Journal of Biological Chemistry ·Takfarinas Kentache,Charlotte R. Althoff,Francesco Caligiore,Erika Souche,Céline Schulz,Julie N. Graff,E. Pieters,Pamela Stanley,Joseph N. Contessa,Emile Van Schaftingen,Gert Matthijs,François Foulquier,Guido T. Bommer,Matthew P. Wilson	2024	2
3	POTENTIAL BENEFITS OF GROUP EXERCISE ON CANCER-RELATED LONELINESS AMONG MEN ENROLLED IN THE GET FIT PROSTATE TRIAL Innovation in Aging ·Kerri M. Winters‐Stone,Sydnee Stoyles,Nathan F. Dieckmann,Karen S. Lyons,Mary E. Crisafio,Arthur Hung,Julie N. Graff,Alexandra Sokolova	2024	0
4	Evolution of structural rearrangements in prostate cancer intracranial metastases npj Precision Oncology ·Francesca Khani,William F. Hooper,Xiaofei Wang,Timothy R. Chu,Minita Shah,Lara Winterkorn,Michael Sigouros,Vincenza Conteduca,David J. Pisapia,Sara E. Wobker,Sydney Walker,Julie N. Graff,Brian D. Robinson,Juan Miguel Mosquera,Andrea Sboner,Olivier Elemento,Nicolas Robine,Himisha Beltran	2023	4
5	Abstract B041: AR suppresses MHC Class I expression and T-cell response in prostate cancer Cancer Research ·Lisa N. Chesner,Julie N. Graff,Fanny Polesso,Alexis Smith,Arian Lundberg,Martin Sjoestroem,Zheng Xia,Simon Linder,Andries M. Bergman,Alan Ashworth,David A. Quigley,Wilbert Zwart,Luke A. Gilbert,Amy E. Moran,Felix Y. Feng	2023	2
6	1771MO Pembrolizumab (pembro) plus enzalutamide (enza) for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Randomized double-blind phase III KEYNOTE-641 study Annals of Oncology ·Julie N. Graff,Mauricio Burotto,Peter C.C. Fong,David Pook,B. Zurawski,Ray Manneh Kopp,Judith Salinas,Kathryn Bylow,Gero Kramer,Raffaele Ratta,Mariusz Kwiatkowski,Margitta Retz,Cheol Kwak,Jóse Ángel Arranz Arija,Howard Gurney,Nobuaki Matsubara,Li Liang,Jelena Todoric,Kentaro Imai,Arnulf Stenzl	2023	13
7	Health-related Quality of Life at the SPARTAN Final Analysis of Apalutamide for Nonmetastatic Castration-resistant Prostate Cancer Patients Receiving Androgen Deprivation Therapy European Urology Focus ·Stéphane Oudard,Boris Hadaschik,Fred Saad,David Cella,Ethan Basch,Julie N. Graff,Hiroji Uemura,Shiva Dibaj,Susan Li,Sabine Brookman‐May,Peter De Porre,Katherine B. Bevans,Jeremiah Trudeau,Eric J. Small,Matthew R. Smith	2021	14
8	Deep Prostate-specific Antigen Response following Addition of Apalutamide to Ongoing Androgen Deprivation Therapy and Long-term Clinical Benefit in SPARTAN European Urology ·Fred Saad,Eric J. Small,Felix Y. Feng,Julie N. Graff,David Olmos,Boris Hadaschik,Stéphane Oudard,Anil Londhe,Amitabha Bhaumik,Angela Lopez‐Gitlitz,Shibu Thomas,Suneel Mundle,Simon Chowdhury,Matthew R. Smith	2021	35
9	Niraparib with androgen receptor-axis-targeted therapy in patients with metastatic castration-resistant prostate cancer: safety and pharmacokinetic results from a phase 1b study (BEDIVERE) Cancer Chemotherapy and Pharmacology ·Fred Saad,Kim N.,Neal D. Shore,Julie N. Graff,Edwin M. Posadas,Jean-Baptiste Lattouf,Byron M. Espina,Eugene Zhu,Alex Yu,Anasuya Hazra,Marc De Meulder,Rao N. V. S. Mamidi,Branislav Bradic,Peter Francis,Vinny Hayreh,Arash Rezazadeh Kalebasty	2021	23
10	632P Health-related quality of life (HRQoL) at final analysis of the SPARTAN study of apalutamide (APA) vs placebo (PBO) in patients (pts) with non-metastatic castration-resistant prostate cancer (nmCRPC) receiving androgen deprivation therapy (ADT) Annals of Oncology ·Stéphane Oudard,Boris Hadaschik,Fred Saad,David Cella,Ethan Basch,Paul N. Mainwaring,Julie N. Graff,Shiva Dibaj,S. Li,S. Brookman-May,Peter De Porre,Jeremiah Trudeau,Eric J. Small,Mitchell R. Smith	2020	3
11	Real-world practice patterns in veterans with metastatic castration-resistant prostate cancer Urologic Oncology Seminars and Original Investigations ·Ahmad Halwani,Kelli M. Rasmussen,Vikas Patil,Catherine C. Li,Christina Yong,Zachary Burningham,Sumati Gupta,Sujata Narayanan,Shih‐Wen Lin,Susheela Carroll,Shivani K. Mhatre,Julie N. Graff,Robert Dreicer,Brian C. Sauer	2019	19
12	Apalutamide and overall survival in non-metastatic castration-resistant prostate cancer Annals of Oncology ·Eric J. Small,Fred Saad,S. Chowdhury,Stéphane Oudard,Boris Hadaschik,Julie N. Graff,David Olmos,Paul N. Mainwaring,J.Y. Lee,Hiroji Uemura,Peter De Porre,Alexis K. Smith,K. Zhang,Angela Lopez‐Gitlitz,Matthew R. Smith	2019	99
13	Practice patterns in metastatic castration-resistant prostate cancer (mCRPC): Evidence from the veterans health administration Annals of Oncology ·Ahmad Halwani,Zachary Burningham,Kelli M. Rasmussen,Vikas Patil,Sujaatha Narayanan,S.-W. Lin,Susheela Carroll,Li Hsu,Julie N. Graff,Robert Dreicer,Sumati Gupta,Clarke A. Low,Brian C. Sauer	2017	2
14	First evidence of significant clinical activity of PD-1 inhibitors in metastatic, castration resistant prostate cancer (mCRPC) Annals of Oncology ·Julie N. Graff,Joshi J. Alumkal,Charles G. Drake,George Thomas,William L. Redmond,Mohammed Farhad,Rachel Slottke,Tomasz M. Beer	2016	27
15	Efficacy and safety of enzalutamide in patients 75 years or older with chemotherapy-naive metastatic castration-resistant prostate cancer: results from PREVAIL Annals of Oncology ·Julie N. Graff,G. Baciarello,Andrew J. Armstrong,C.S. Higano,Pernille Iversen,Thomas W. Flaig,David Forer,Teresa Parli,D. Phung,Bertrand Tombal,Tomasz M. Beer,C. Sternberg	2015	86
16	Safety and effectiveness of enzalutamide in men with metastatic, castration-resistant prostate cancer Expert Opinion on Pharmacotherapy ·Julie N. Graff,Max J. Gordon,Tomasz M. Beer	2015	8
17	Sustained Complete Response to CTLA-4 Blockade in a Patient with Metastatic, Castration-Resistant Prostate Cancer Cancer Immunology Research ·Julie N. Graff,Sachin Puri,Carlo Bifulco,Bernard A. Fox,Tomasz M. Beer	2014	29
18	Sipuleucel-T in the treatment of prostate cancer: an evidence-based review of its place in therapy PubMed ·Julie N. Graff,Erin Chamberlain	2014	53
19	Pharmacotherapeutic Management of Metastatic, Castration-Resistant Prostate Cancer in the Elderly: Focus on Non-Chemotherapy Agents Drugs & Aging ·Julie N. Graff,Tomasz M. Beer	2014	11
20	C-reactive protein as an adverse prognostic marker for men with castration-resistant prostate cancer (CRPC): Confirmatory results Urologic Oncology Seminars and Original Investigations ·R. Prins,Brooks L. Rademacher,Solange Mongoue‐Tchokote,Joshi J. Alumkal,Julie N. Graff,Kristine M. Eilers,Tomasz M. Beer	2010	49

About Julie N. Graff

Julie N. Graff is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research, having authored 104 papers that have together received 3.2k indexed citations. Recurring topics across this work include Prostate Cancer Treatment and Research (84 papers), Radiopharmaceutical Chemistry and Applications (39 papers), Cancer Immunotherapy and Biomarkers (21 papers), Cancer, Lipids, and Metabolism (19 papers), Prostate Cancer Diagnosis and Treatment (10 papers), Immunotherapy and Immune Responses (10 papers), PARP inhibition in cancer therapy (9 papers) and Cancer Treatment and Pharmacology (7 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (2.3k citations), Cancer Research (769 citations) and Oncology (1.2k citations). Julie N. Graff has collaborated with scholars based in United States, Canada and United Kingdom. Frequent co-authors include Tomasz M. Beer, Fred Saad, Eric J. Small, Angela Lopez‐Gitlitz, Matthew R. Smith, Boris Hadaschik, Stéphane Oudard, Paul N. Mainwaring, David Olmos and Hiroji Uemura. Their work appears in journals such as Nature, New England Journal of Medicine and Journal of Biological Chemistry.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact